157 related articles for article (PubMed ID: 28694503)
1. CD44v8-10 as a potential theranostic biomarker for targeting disseminated cancer cells in advanced gastric cancer.
Choi ES; Kim H; Kim HP; Choi Y; Goh SH
Sci Rep; 2017 Jul; 7(1):4930. PubMed ID: 28694503
[TBL] [Abstract][Full Text] [Related]
2. Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer.
Hagiwara M; Kikuchi E; Tanaka N; Kosaka T; Mikami S; Saya H; Oya M
BMC Cancer; 2018 Jan; 18(1):113. PubMed ID: 29385995
[TBL] [Abstract][Full Text] [Related]
3. Regulation of CD44v6 expression in gastric carcinoma by the IL-6/STAT3 signaling pathway and its clinical significance.
Xu YY; Guo M; Yang LQ; Zhou F; Yu C; Wang A; Pang TH; Wu HY; Zou XP; Zhang WJ; Wang L; Xu GF; Huang Q
Oncotarget; 2017 Jul; 8(28):45848-45861. PubMed ID: 28507278
[TBL] [Abstract][Full Text] [Related]
4. CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis.
Sosulski A; Horn H; Zhang L; Coletti C; Vathipadiekal V; Castro CM; Birrer MJ; Nagano O; Saya H; Lage K; Donahoe PK; Pépin D
PLoS One; 2016; 11(6):e0156595. PubMed ID: 27253518
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD44 variant exons 8-10 in gastric cancer.
Yamaguchi A; Saito M; Gio T; Iida A; Takeuchi K; Hirose K; Nakagawara G; Urano T; Furukawa K; Shiku H
Jpn J Cancer Res; 1995 Dec; 86(12):1166-71. PubMed ID: 8636005
[TBL] [Abstract][Full Text] [Related]
6. CD82 suppresses CD44 alternative splicing-dependent melanoma metastasis by mediating U2AF2 ubiquitination and degradation.
Zhang P; Feng S; Liu G; Wang H; Fu A; Zhu H; Ren Q; Wang B; Xu X; Bai H; Dong C
Oncogene; 2016 Sep; 35(38):5056-5069. PubMed ID: 27041584
[TBL] [Abstract][Full Text] [Related]
7. Impact of Truncated
Moreira IB; Pinto F; Gomes C; Campos D; Reis CA
Cells; 2020 Jan; 9(2):. PubMed ID: 31973075
[TBL] [Abstract][Full Text] [Related]
8. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells.
Lau WM; Teng E; Chong HS; Lopez KA; Tay AY; Salto-Tellez M; Shabbir A; So JB; Chan SL
Cancer Res; 2014 May; 74(9):2630-41. PubMed ID: 24618343
[TBL] [Abstract][Full Text] [Related]
9. A CD44-specific peptide, RP-1, exhibits capacities of assisting diagnosis and predicting prognosis of gastric cancer.
Li W; Jia H; Wang J; Guan H; Li Y; Zhang D; Tang Y; Wang TD; Lu S
Oncotarget; 2017 May; 8(18):30063-30076. PubMed ID: 28415792
[TBL] [Abstract][Full Text] [Related]
10. CD44 Variant 9 Serves as a Poor Prognostic Marker in Early Gastric Cancer, But Not in Advanced Gastric Cancer.
Go SI; Ko GH; Lee WS; Kim RB; Lee JH; Jeong SH; Lee YJ; Hong SC; Ha WS
Cancer Res Treat; 2016 Jan; 48(1):142-52. PubMed ID: 25779358
[TBL] [Abstract][Full Text] [Related]
11. De novo expression of CD44 variants in sporadic and hereditary gastric cancer.
da Cunha CB; Oliveira C; Wen X; Gomes B; Sousa S; Suriano G; Grellier M; Huntsman DG; Carneiro F; Granja PL; Seruca R
Lab Invest; 2010 Nov; 90(11):1604-14. PubMed ID: 20856229
[TBL] [Abstract][Full Text] [Related]
12. Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality.
Hagiwara M; Kikuchi E; Kosaka T; Mikami S; Saya H; Oya M
Urol Oncol; 2016 Aug; 34(8):337.e19-26. PubMed ID: 27133224
[TBL] [Abstract][Full Text] [Related]
13. In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells.
Mashima T; Iwasaki R; Kawata N; Kawakami R; Kumagai K; Migita T; Sano T; Yamaguchi K; Seimiya H
Br J Cancer; 2019 Nov; 121(10):846-856. PubMed ID: 31607750
[TBL] [Abstract][Full Text] [Related]
14. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer.
Yoshida K; Tsujimoto H; Matsumura K; Kinoshita M; Takahata R; Matsumoto Y; Hiraki S; Ono S; Seki S; Yamamoto J; Hase K
Cancer Med; 2015 Sep; 4(9):1322-33. PubMed ID: 26077800
[TBL] [Abstract][Full Text] [Related]
15. Isolation and characterization of circulating tumor cells from human gastric cancer patients.
Yuan D; Chen L; Li M; Xia H; Zhang Y; Chen T; Xia R; Tang Q; Gao F; Mo X; Liu M; Bi F
J Cancer Res Clin Oncol; 2015 Apr; 141(4):647-60. PubMed ID: 25326346
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer.
Kodama H; Murata S; Ishida M; Yamamoto H; Yamaguchi T; Kaida S; Miyake T; Takebayashi K; Kushima R; Tani M
Br J Cancer; 2017 Jan; 116(2):186-194. PubMed ID: 27931044
[TBL] [Abstract][Full Text] [Related]
17. Targeted eradication of gastric cancer stem cells by CD44 targeting USP22 small interfering RNA-loaded nanoliposomes.
Yang F; Zheng Z; Xue X; Zheng L; Qin J; Li H; Zhou Y; Fang G
Future Oncol; 2019 Jan; 15(3):281-295. PubMed ID: 30543303
[TBL] [Abstract][Full Text] [Related]
18. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
Yan Y; Zuo X; Wei D
Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
[TBL] [Abstract][Full Text] [Related]
19. Chitinase 3-like 1-CD44 interaction promotes metastasis and epithelial-to-mesenchymal transition through β-catenin/Erk/Akt signaling in gastric cancer.
Geng B; Pan J; Zhao T; Ji J; Zhang C; Che Y; Yang J; Shi H; Li J; Zhou H; Mu X; Xu C; Wang C; Xu Y; Liu Z; Wen H; You Q
J Exp Clin Cancer Res; 2018 Aug; 37(1):208. PubMed ID: 30165890
[TBL] [Abstract][Full Text] [Related]
20. DC - SIGNR by influencing the lncRNA HNRNPKP2 upregulates the expression of CXCR4 in gastric cancer liver metastasis.
Zhang Y; Zhang Q; Zhang M; Yuan M; Wang Z; Zhang J; Zhou X; Zhang Y; Lin F; Na H; Ren S; Zuo Y
Mol Cancer; 2017 Apr; 16(1):78. PubMed ID: 28403883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
